Clinical Trial Update: Faslodex in McCune-Albright Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Faslodex in McCune-Albright Syndrome and precocious puberty, completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mccune-albright Syndrome
• Precocious Puberty

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Puberty, Precocious, McCune-Albright Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2011-07-19